Director Eli Lilly and Company Indianapolis, Indiana
Currently, continuous direct compression (CDC) is the preferred drug product manufacturing platform for the development of new chemical entities (NCE) at Lilly. A network of identical CDC facilities enables this across development and GMP Lilly sites as well as internal experience with more than a dozen formulations and an approved product on multiple markets with CDC. This presentation will share current perspectives from Lilly on the use of CDC for the development and commercialization of NCEs. Data will be shared highlighting development speed and efficiency, higher assurance of quality, and ease of technical transfer with continuous manufacturing.
Understand main drivers for implementing continuous manufacturing in the pharma industry.
Explore how continuous manufacturing can help achieve more efficient development approaches.
Discuss how CM enables use of simpler drug product formulations and simpler manufacturing processes.
Share examples for how CM can enable use of platform understanding across multiple molecules, and allows for lower technical transfer risks.